» Articles » PMID: 12239179

Frequency and Load of Hepatitis B Virus DNA in First-time Blood Donors with Antibodies to Hepatitis B Core Antigen

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2002 Sep 20
PMID 12239179
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to determine the frequency and load of hepatitis B virus (HBV) DNA in anti-HBc-positive first-time blood donors; it was designed to contribute to determining whether anti-HBc screening of blood donations might reduce the residual risk of posttransfusion HBV infection. A total of 14 251 first-time blood donors were tested for anti-HBc using a microparticle enzyme immunoassay; positive results were confirmed by a second enzyme-linked immunosorbent assay (ELISA). For the detection of HBV DNA from plasma samples, we developed a novel and highly sensitive real-time polymerase chain reaction (PCR) assay. The 95% detection limit of the method amounted to 27.8 IU/mL, consistent with the World Health Organization (WHO) international standard for HBV DNA. A total of 216 blood donors (1.52%) tested anti-HBc-positive in both tests, and 205 of them (16 HBsAg(+), 189 HBsAg(-)) were tested for HBV DNA. In 14 (87.5%) of the HBsAg-positive blood donors, HBV DNA was repeatedly detected, and in 3 (1.59%) of the HBsAg-negative donors, HBV DNA was also found repeatedly. In the 3 HBV DNA-positive, HBsAg-negative cases, anti-HBe and anti-HBs (> 100 IU/L) were also detectable. HBV DNA in HBsAg-negative as well as HBsAg-positive samples was seen at a low level. Thus, HBV DNA is sometimes found in HBsAg-negative, anti-HBc-positive, and anti-HBs-positive donors. Retrospective studies on regular blood donors and recipients are necessary to determine the infection rate due to those donations. Routine anti-HBc screening of blood donations could probably prevent some transfusion-transmitted HBV infections.

Citing Articles

Hepatitis B virus (HBV) serological patterns among the HBsAg negative hospital attendees screened for immunization.

Kafeero H, Ndagire D, Ocama P, Drago Kato C, Wampande E, Walusansa A Sci Rep. 2022; 12(1):7425.

PMID: 35523938 PMC: 9076922. DOI: 10.1038/s41598-022-11535-8.


A Study of Prevalence of Occult Hepatitis B Virus Infection, Knowledge and Preventive Practices Against Hepatitis B Virus in Barbers Serving the Armed Forces.

Sood A, Pathak S, Khandelwal N J Clin Exp Hepatol. 2021; 11(6):668-673.

PMID: 34866845 PMC: 8617542. DOI: 10.1016/j.jceh.2021.02.005.


A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus.

Kiruthika S, Bhat R, Dash R, Rathore A, Vivekanandan P, Jayaram B Sci Rep. 2021; 11(1):11723.

PMID: 34083665 PMC: 8175705. DOI: 10.1038/s41598-021-91196-1.


Real Time Polymerase Chain Reaction for Hepatitis B Screening in Donor Corneas in the Central Eye Bank of Iran.

Samiee S, Kanavi M, Javadi M, Bagheri A, Balagholi S, Hashemi M J Ophthalmic Vis Res. 2018; 13(4):392-396.

PMID: 30479707 PMC: 6210878. DOI: 10.4103/jovr.jovr_157_17.


Prevalence and characterization of occult hepatitis B infection among blood donors in central Saudi Arabia.

Alshayea A, Eid G, El-Hazmi M, Alhetheel A Saudi Med J. 2016; 37(10):1114-9.

PMID: 27652363 PMC: 5075376. DOI: 10.15537/smj.2016.10.14708.